Etiome’s Temporal Biodynamics™ AI-powered platform is the first end-to-end solution to detect disease and preempt progression before it becomes too late
Flagship Pioneering, the bioplatform innovation company, unveiled Etiome, a company redefining how we detect and preempt disease progression. Etiome’s Temporal Biodynamics platform is the first end-to-end technology to characterize disease with increased resolution over time and accelerate the development of preemptive medicines that promise better health outcomes for people at risk of chronic or progressive diseases. The AI-powered platform makes it possible to forecast how individuals are likely to progress along the disease continuum, confirm disease biostages with temporally relevant markers, and develop Biostaged Medicines to halt or reverse disease before it becomes debilitating and irreversible. Flagship has initially committed $50 million to Etiome to advance the Temporal Biodynamics™ platform and develop an initial pipeline of preemptive medicines. Etiome was founded from Flagship Pioneering’s Preemptive Health and Medicine Initiative, which is pioneering a new field to protect, maintain, or improve people’s health before they get sick.
Health Technology Insights: Free Market Health Acquires Beeline Rx, Enhances with AI Onboarding
“By combining expansive, multimodal population-level data and single cell omics with artificial intelligence, we have, for the first time, revealed unprecedented insights into the complex dynamics of disease biology over the course of progression,” said Avak Kahvejian, Ph.D., Founding CEO of Etiome and General Partner at Flagship Pioneering. “In doing so, with our Temporal Biodynamics™ platform we have unlocked the ability to accurately characterize the biostages of disease progression, selectively identify and engage patients across stages, and create targeted medicines designed to alter the course of disease, even at its earliest stages, ensuring the right patient gets the right medicine at the right time.”
Etiome designed the Temporal Biodynamics™ platform based on an understanding that the underlying biology of disease is dynamic and will mandate stage-specific interventions to effectively impact progression. To pioneer these targeted preemptive medicines, the platform first leverages expansive clinical, cellular, and molecular data and artificial intelligence to develop a deeper, time-based understanding of disease biology and forecast when individuals are likely to progress further into disease. With proprietary phenotype-aware AI, the platform then isolates and uncovers underlying temporal shifts in thousands of genes and proteins specific to each disease, revealing unique Biostage Markers—stage-specific biomarkers that indicate where a patient resides along the disease journey—and potential stage-appropriate therapeutic targets. Finally, temporally tuned, translational assays allow for target validation and the development of Biostaged Medicines.
Health Technology Insights: 1Cell.Ai Launches OncoIncytes for Precision Oncology Data Integration
“Until now, healthcare practices for serious and progressive diseases have often been reactive, treating diseases after they have caused significant damage and resulting in patient decline that can be irreversible,” said Raj Panjabi, M.D., MPH, Senior Partner and Head of Flagship Pioneering’s Preemptive Health and Medicine Initiative and board director of Etiome. “Etiome is redefining how we think about disease progression and developing interventions precisely designed for critical intervention windows, at the earliest stages of disease – helping to slow, stop or even reverse it. This represents a significant shift towards preemptive medicine—a future where people can live healthier and longer lives.”
Etiome is initially focused on developing Biostaged Medicines to address serious and progressive metabolic, neurodegenerative, pre-cancerous and autoimmune diseases, all of which impact large populations and have clear unmet needs. With these targeted therapeutics, Etiome aims to reduce morbidity, lower healthcare burdens and costs, and extend healthy and productive lifespans.
Scott Lipnick, Ph.D., Co-Founder and President of Etiome and Flagship Pioneering Origination Partner, added, “We envision a world where patients can be treated for a disease when it is still possible to slow, stop, or entirely preempt its progression. Doing so can prevent suffering, save lives, and lower healthcare costs. Over the last four years we have been building Etiome around this vision and look forward to making meaningful and rapid progress towards this future.”
Etiome’s team includes leaders with extensive expertise in biology, omics, and artificial intelligence. In addition to Kahvejian and Lipnick, Etiome’s founding team includes Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering; Torben Straight Nissen, Ph.D., Chairman of the Board for Etiome, Flagship Pioneering Executive Partner and CEO of Repertoire Immune Medicines; Yann Echelard, Ph.D., Chief Operating Officer of Etiome and Flagship Pioneering Operating Partner; and Katharine von Herrmann, Ph.D., Chief Innovation Officer of Etiome and Flagship Pioneering Principal. Additionally, the Etiome board includes Gregory J. Moore M.D., Ph.D., a Senior Advisor at Gates Ventures and the former Corporate Vice President at Microsoft leading Health and Life Sciences.
Health Technology Insights: Iowa State, When Partner to Offer Grads Affordable Insurance
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
